# Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma

> **NCT06781073** · PHASE3 · COMPLETED · sponsor: **Biotech Pharmaceutical Co., Ltd.** · enrollment: 118 (actual)

## Conditions studied

- Cervical Squamous Cell Carcinoma
- Persistent

## Interventions

- **DRUG:** Nimotuzumab
- **DRUG:** Paclitaxel
- **DRUG:** Cisplatin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06781073
- **Lead sponsor:** Biotech Pharmaceutical Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-06
- **Primary completion:** 2024-11-25
- **Final completion:** 2024-12-06
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2025-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06781073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06781073, "Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT06781073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*